I'm LongbridgeAI, I can summarize articles.The Week
Kenvue has no valid weekly price data for this period, and the stock is now delisted. The last quote sits at $19.31, unchanged from the prior close, with zero volume. The S&P 500 fell 2.68% this week. Since Kenvue is delisted, there is no meaningful comparison with the broader market, so the price section stops here.
Key Events
The main story this week was Kimberly-Clark completing its acquisition of Kenvue. On Monday 2 November, the deal was confirmed done, and Kenvue merged with K-C. The same day, reports said cybersecurity firm Okta would replace Tylenol maker Kenvue in the S&P 500. On Tuesday 3 November, Kimberly-Clark announced the expiration and final results of exchange offers for Kenvue notes, and on Thursday 5 November it reported $6.38 billion tendered in senior unsecured debt exchange. Kenvue then eliminated most restrictive debt covenants. Thursday also brought conditional approval from Colombia for the acquisition, and Mirae Asset Global Investments disclosed a new purchase of Kenvue shares. Kimberly-Clark reported Q3 results on the same day, with diluted EPS up to $5.37 and net sales down to $4.1 billion. Management kicked off Kenvue integration with a $1.9 billion cost-synergy target. Overall, this was a week of deal completion, debt exchange, and index removal.
Analyst Ratings
On coverage, the sample shows 1 strong buy, 1 buy, 12 hold, 0 under, and 0 sell, for a total of 14. Consensus rating is hold, with a consensus target of $19.50, about 0.98% above spot. The target range is not provided, so dispersion cannot be judged, and no industry rating rank is available. Neutral ratings dominate, with only 2 buy-side views combined.
The Week Ahead
Kenvue is delisted and now sits inside Kimberly-Clark integration, with no standalone earnings or events on the calendar. On the macro side, Tuesday 10 November brings US CPI and core CPI numbers. Core CPI shows a prior reading of 2.6 and a forecast of 2.8, while headline CPI prior sits at 0.59. NFIB small business optimism is also due, with a prior of 97.9. For a delisted Kenvue, the more relevant watch items are the remaining debt exchange and cost-synergy execution.
In Short
The core facts this week were deal completion, debt exchange, and removal from the S&P 500, with no trading left in the stock itself. Ratings are neutral-led and the consensus target is only about 1% above spot; latest snapshots show zero flows across large, medium, and small orders, consistent with a delisted status. The tension is between the start of integration with a $1.9 billion synergy target and the exit from the index with zero volume. What matters next is not Kenvue itself but Kimberly-Clark’s execution and the read-through for consumer health.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.